GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190332031 | Stomach | CAG | regulation of protein modification by small protein conjugation or removal | 24/552 | 242/18723 | 2.30e-07 | 1.90e-05 | 24 |
GO:003139631 | Stomach | CAG | regulation of protein ubiquitination | 22/552 | 210/18723 | 2.84e-07 | 2.30e-05 | 22 |
GO:199074831 | Stomach | CAG | cellular detoxification | 16/552 | 116/18723 | 3.00e-07 | 2.39e-05 | 16 |
GO:00975013 | Stomach | CAG | stress response to metal ion | 7/552 | 19/18723 | 6.90e-07 | 4.81e-05 | 7 |
GO:190290331 | Stomach | CAG | regulation of supramolecular fiber organization | 30/552 | 383/18723 | 1.27e-06 | 8.20e-05 | 30 |
GO:000697931 | Stomach | CAG | response to oxidative stress | 33/552 | 446/18723 | 1.33e-06 | 8.49e-05 | 33 |
GO:004254231 | Stomach | CAG | response to hydrogen peroxide | 17/552 | 146/18723 | 1.48e-06 | 9.18e-05 | 17 |
GO:00988693 | Stomach | CAG | cellular oxidant detoxification | 14/552 | 101/18723 | 1.55e-06 | 9.34e-05 | 14 |
GO:200011631 | Stomach | CAG | regulation of cysteine-type endopeptidase activity | 22/552 | 235/18723 | 1.93e-06 | 1.11e-04 | 22 |
GO:004217631 | Stomach | CAG | regulation of protein catabolic process | 30/552 | 391/18723 | 1.94e-06 | 1.11e-04 | 30 |
GO:000838021 | Stomach | CAG | RNA splicing | 32/552 | 434/18723 | 2.08e-06 | 1.16e-04 | 32 |
GO:190336231 | Stomach | CAG | regulation of cellular protein catabolic process | 23/552 | 255/18723 | 2.14e-06 | 1.18e-04 | 23 |
GO:00102733 | Stomach | CAG | detoxification of copper ion | 6/552 | 15/18723 | 2.55e-06 | 1.35e-04 | 6 |
GO:19901693 | Stomach | CAG | stress response to copper ion | 6/552 | 15/18723 | 2.55e-06 | 1.35e-04 | 6 |
GO:00513463 | Stomach | CAG | negative regulation of hydrolase activity | 29/552 | 379/18723 | 3.03e-06 | 1.54e-04 | 29 |
GO:004854531 | Stomach | CAG | response to steroid hormone | 27/552 | 339/18723 | 3.15e-06 | 1.55e-04 | 27 |
GO:00104663 | Stomach | CAG | negative regulation of peptidase activity | 23/552 | 262/18723 | 3.39e-06 | 1.65e-04 | 23 |
GO:190357331 | Stomach | CAG | negative regulation of response to endoplasmic reticulum stress | 9/552 | 44/18723 | 4.45e-06 | 2.09e-04 | 9 |
GO:005134831 | Stomach | CAG | negative regulation of transferase activity | 23/552 | 268/18723 | 4.96e-06 | 2.30e-04 | 23 |
GO:004586131 | Stomach | CAG | negative regulation of proteolysis | 27/552 | 351/18723 | 6.02e-06 | 2.75e-04 | 27 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AR | SNV | Missense_Mutation | | c.2595N>A | p.Asp865Glu | p.D865E | P10275 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
AR | SNV | Missense_Mutation | | c.1912N>A | p.Leu638Met | p.L638M | P10275 | protein_coding | tolerated(0.07) | benign(0.316) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
AR | SNV | Missense_Mutation | novel | c.1082N>A | p.Ser361Asn | p.S361N | P10275 | protein_coding | tolerated_low_confidence(0.27) | benign(0.015) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1681N>A | p.Leu561Met | p.L561M | P10275 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1703C>T | p.Ser568Phe | p.S568F | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
AR | SNV | Missense_Mutation | novel | c.2642N>A | p.Leu881Gln | p.L881Q | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A66K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | novel | c.585N>T | p.Gln195His | p.Q195H | P10275 | protein_coding | tolerated_low_confidence(0.13) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.2718N>T | p.Lys906Asn | p.K906N | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.967N>A | p.Glu323Lys | p.E323K | P10275 | protein_coding | tolerated_low_confidence(0.11) | benign(0.265) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
AR | SNV | Missense_Mutation | | c.2462G>T | p.Gly821Val | p.G821V | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | FLUOCINOLONE ACETONIDE | FLUOCINOLONE ACETONIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 4-CHLOROMERCURIBENZOIC ACID | 4-CHLOROMERCURIBENZOIC ACID | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | agonist | CHEMBL2107067 | TESTOSTERONE UNDECANOATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | DIDECYLDIMETHYLAMMONIUM CHLORIDE | DIDECYLDIMETHYLAMMONIUM CHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | QUININE SULFATE | QUININE SULFATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | NILUTAMIDE | NILUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | RALOXIFENE HYDROCHLORIDE | RALOXIFENE HYDROCHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | ARN-509 | APALUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | CRUFOMATE | CRUFOMATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 2-AMINOFLURENE | CHEMBL84472 | |